NM_000089.4(COL1A2):c.2206G>T (p.Gly736Cys)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta|Osteogenesis imperfecta with normal sclerae, dominant form
β
β
ββ2026β Residue 736
NM_000089.4(COL1A2):c.326G>A (p.Gly109Asp)Pathogenic
Osteogenesis imperfecta type I|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2|Cardiovascular phenotype|not provided
β
β
ββ2026β Residue 109
NM_000089.4(COL1A2):c.1576G>A (p.Gly526Arg)Pathogenic
Osteogenesis imperfecta, perinatal lethal|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2|not provided|Osteogenesis imperfecta type I|Cardiovascular phenotype
β
β
ββ2026β Residue 526
NM_000089.4(COL1A2):c.892G>A (p.Gly298Ser)Pathogenic
Osteogenesis imperfecta|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2
β
β
ββ2026β Residue 298
NM_000089.4(COL1A2):c.1199G>C (p.Gly400Ala)Pathogenic
Ehlers-Danlos syndrome, cardiac valvular type|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1
β
β
ββ2026β Residue 400
NM_000089.4(COL1A2):c.1171G>A (p.Gly391Ser)Pathogenic
Osteogenesis imperfecta with normal sclerae, dominant form|not provided|Dentinogenesis imperfecta|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta|COL1A2-related disorder
β
β
ββ2026β Residue 391
NM_000089.4(COL1A2):c.2081G>A (p.Gly694Asp)Pathogenic
Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|not provided|Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, cardiac valvular type
β
β
ββ2026β Residue 694
NM_000089.4(COL1A2):c.2755G>A (p.Gly919Ser)Pathogenic
not provided|Cardiovascular phenotype|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Ehlers-Danlos syndrome, cardiac valvular type;Ehlers-Danlos syndrome, arthrochalasia type;Osteogenesis imperfecta|COL1A2-related disorder|Osteogenesis imperfecta with normal sclerae, dominant form;Osteogenesis imperfecta, perinatal lethal;Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, arthrochalasia type, 2
β
β
ββ2026β Residue 919
NM_000089.4(COL1A2):c.2711G>C (p.Gly904Ala)Likely pathogenic
Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|not provided
β
β
ββ2026β Residue 904
NM_000089.4(COL1A2):c.577G>A (p.Gly193Ser)Pathogenic
not provided|Osteogenesis imperfecta type I|Postmenopausal osteoporosis|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|7 conditions|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2
β
β
ββ2026β Residue 193
NM_000089.4(COL1A2):c.298G>A (p.Gly100Ser)Pathogenic
Osteogenesis imperfecta type I|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|not provided|Ehlers-Danlos syndrome|COL1A2-related disorder|Cardiovascular phenotype
β
β
ββ2026β Residue 100
NM_000089.4(COL1A2):c.2701G>A (p.Gly901Ser)Pathogenic
not provided|Ehlers-Danlos syndrome|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|COL1A2-related osteogenesis imperfecta|Ehlers-Danlos syndrome, arthrochalasia type, 2
β
β
ββ2025β Residue 901
NM_000089.4(COL1A2):c.1072G>A (p.Gly358Ser)Pathogenic
not provided|Osteogenesis imperfecta, perinatal lethal|Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|7 conditions
β
β
ββ2025β Residue 358
NM_000089.4(COL1A2):c.2027G>C (p.Gly676Ala)Pathogenic
not provided|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1
β
β
ββ2025β Residue 676
NM_000089.4(COL1A2):c.389G>A (p.Gly130Asp)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I
β
β
ββ2025β Residue 130
NM_000089.4(COL1A2):c.1892G>T (p.Gly631Val)Pathogenic
Osteogenesis imperfecta with normal sclerae, dominant form|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Osteogenesis imperfecta type III
β
β
ββ2025β Residue 631
NM_000089.4(COL1A2):c.1972G>T (p.Gly658Cys)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I
β
β
ββ2025β Residue 658
NM_000089.4(COL1A2):c.1009G>A (p.Gly337Ser)Pathogenic
Osteogenesis imperfecta type I|Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, classic type|Osteogenesis imperfecta with normal sclerae, dominant form;Osteogenesis imperfecta type III|not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta|Ehlers-Danlos syndrome, arthrochalasia type, 2|Ehlers-Danlos syndrome|COL1A2-related disorder|Osteogenesis imperfecta with normal sclerae, dominant form
β
β
ββ2025β Residue 337
NM_000089.4(COL1A2):c.2314G>A (p.Gly772Ser)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta with normal sclerae, dominant form|Osteogenesis imperfecta|Ehlers-Danlos syndrome, arthrochalasia type, 2
β
β
ββ2025β Residue 772
NM_000089.4(COL1A2):c.451G>A (p.Gly151Arg)Pathogenic
Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|COL1A2-related disorder|Osteogenesis imperfecta type I
β
β
ββ2025β Residue 151